You searched for baricitinib - Page 5 of 20

Abstract Number: 1880 • 2019 ACR/ARP Annual Meeting
Baricitinib 4 Mg and 2 Mg Once Daily Reduced Pain in Both Patients Who Were Opioid Users and Non-users in Active Rheumatoid Arthritis: A Post-hoc Analysis of Phase 3 Trials
Janet Pope¹, Yvonne Lee ², Jeffrey Curtis ³, Daojun Mo ⁴, Terence Rooney ⁴, Li Xie ⁴, Christina Dickson ⁴, Douglas Schlichting ⁴, Amanda Quebe ⁴, Anabela Cardoso ⁴, Lee Simon ⁵ and Peter Taylor ⁶, ¹Western University, London, ON, Canada, ²Northwestern University Feinberg School of Medicine, Chicago, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵SDG LLC, Cambridge, MA, ⁶University of Oxford, Oxford, United Kingdom
Background/Purpose: Opioid use in RA patients has increased over the past 2 decades in the US. Little is known about the combined effects of opioids…
Abstract Number: 2375 • 2019 ACR/ARP Annual Meeting
Safety of Baricitinib Under Clinical Settings in Patients with Rheumatoid Arthritis, Using Data from All-Case Post-marketing Surveillance and Spontaneous Reports
Hiroaki Matsuno ¹, Tatsuya Atsumi ², Shuji Takei ³, Naoto Tamura ⁴, Masayoshi Harigai ⁵, Takao Fujii ⁶, Shigeki Momohara ⁷, Yuko Takahashi ⁸, Nobuhiro Narii ⁸, Naoto Tsujimoto ⁸, Atsushi Nishikawa ⁸, Taeko Ishii⁸, Kazuhiko Yamamoto ⁹, Masataka Kuwana ¹⁰ and Michiaki Takagi ¹¹, ¹Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, ²Hokkaido University, Sapporo, Japan, ³Kagoshima University, Kagoshima, Japan, ⁴Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ⁵Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁶Wakayama Medical University, Wakayama, Japan, ⁷Hakkeikai Incorporated Medical Institution, Shizuoka, Japan, ⁸Eli Lilly Japan K.K., Kobe, Japan, ⁹Riken Center for Integrative Medical Sciences, Kanagawa, Japan, ¹⁰Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ¹¹Yamagata University Faculty of Medicine, Yamagata-shi, Japan
Background/Purpose: Baricitinib (bari), is an oral, selective inhibitor of Janus kinase (JAK) 1/ and JAK 2, is used to treat moderately to severely active RA…
Abstract Number: 546 • 2018 ACR/ARHP Annual Meeting
Baricitinib: Early Vs. Delayed Start in Patients with Rheumatoid Arthritis
Peter C. Taylor¹, Yoshiya Tanaka², Anabela Cardoso³, Jinglin Zhong⁴, Yun-Fei Chen³, Jennifer Lynn Workman³, Liliana del Carmen Morales⁵ and Michael Schiff⁶, ¹Botnar Research Centre, Univ of Oxford, Oxford, United Kingdom, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Eli Lilly and Company, Indianapolis, IN, ⁴IQVIA, Morrisville, NC, ⁵INStituto Reumatologica Strusberg, Cordoba, Argentina, ⁶University of Colorado, Greenwood Village, CO
Background/Purpose: Baricitinib (bari) is an oral JAK1/JAK2 inhibitor approved for the treatment of moderately to severely active RA in adults in over 40 countries including…
Abstract Number: 574 • 2018 ACR/ARHP Annual Meeting
Longitudinal Efficacy Analysis of Patients with Active Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Dmards: Response Following Rescue from Baricitinib 2mg to 4mg Once-Daily
Roy Fleischmann¹, Mark C. Genovese², Anabela Cardoso³, Luna Sun³, Yun-Fei Chen³, Chad D. Walls³, Douglas E. Schlichting³, Tsutomu Takeuchi⁴, Maxime Dougados⁵, Josef S. Smolen⁶ and Jeffrey R. Curtis⁷, ¹Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, ²Stanford University Medical Center, Palo Alto, CA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keio University School of Medicine, Tokyo, Japan, ⁵Paris Descartes University, Hôpital Cochin, Paris, France, ⁶Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁷University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Baricitinib (bari), an oral selective Janus kinase 1/2 inhibitor, has shown clinical efficacy in patients (pts) with RA and an inadequate response to conventional…
Abstract Number: 599 • 2018 ACR/ARHP Annual Meeting
Comparative Effectiveness in Pain and HAQ-DI Improvement for Baricitinib Versus Adalimumab, Tocilizumab, and Tofacitinib Monotherapies in Csdmard-Naïve Rheumatoid Arthritis Patients: A Matching-Adjusted Indirect Comparison (MAIC)
Bruno Fautrel¹, Baojin Zhu², Peter C. Taylor³, Mart van de Laar⁴, Paul Emery⁵, Francesco de Leonardis², Carol L. Gaich², Claudia Nicolay², Zbigniew Kadziola², Inmaculada de la Torre⁶ and Roy Fleischmann⁷, ¹University Pierre et Marie Curie, Paris, France, ²Eli Lilly and Company, Indianapolis, IN, ³Botnar Research Centre, Univ of Oxford, Oxford, United Kingdom, ⁴Arthritis Centre Twente, University of Twente, Enschede, Netherlands, ⁵Leeds MSK Biomed/Chapel Allerton Hospital, Leeds, United Kingdom, ⁶Eli Lilly and Company, Madrid, Spain, ⁷Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: In Phase 3 trial (RA-BEGIN), baricitinib (BARI) monotherapy demonstrated superiority to MTX in pain reduction and HAQ-DI improvement in treatment of csDMARD-naïve active RA…
Abstract Number: 886 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Switching from Adalimumab to Baricitinib: Long-Term Data from Phase 3 Extension Study in Patients with Rheumatoid Arthritis
Michael E Weinblatt¹, Peter C. Taylor², Edward C. Keystone³, Robert A. Ortmann⁴, Maher Issa⁴, Li Xie⁴, Stephanie de Bono⁴ and Yoshiya Tanaka⁵, ¹Brigham and Women’s Hospital, Boston, MA, ²Botnar Research Centre, Univ of Oxford, Oxford, United Kingdom, ³Mount Sinai Hospital, Toronto, ON, Canada, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Baricitinib (bari) is an oral JAK1/JAK2 inhibitor approved for the treatment of moderately to severely active RA in adults in over 40 countries, including…
Abstract Number: 962 • 2018 ACR/ARHP Annual Meeting
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 6 Years: An Updated Integrated Safety Analysis
Mark C. Genovese¹, Josef S. Smolen², Tsutomu Takeuchi³, Terence P. Rooney⁴, Christina L. Dickson⁴, Xiao-Yan Yang⁴, Chadi Saifan⁴, Anabela Cardoso⁴, Maher Issa⁴, Taeko Ishii⁵ and Kevin Winthrop⁶, ¹Stanford University Medical Center, Palo Alto, CA, ²Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly and Company, Kobe, Japan, ⁶Oregon Health and Science University, Portland, OR
Background/Purpose: Baricitinib (bari), an oral, selective inhibitor of Janus kinase (JAK) 1 and JAK 2, is approved for the treatment of moderately to severely active…
Abstract Number: 970 • 2018 ACR/ARHP Annual Meeting
Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Daniel J. Wallace¹, Richard Furie², Yoshiya Tanaka³, Kenneth C. Kalunian⁴, Marta Mosca⁵, Michelle Petri⁶, Thomas Dorner⁷, Mario H. Cardiel⁸, Ian N. Bruce⁹, Elisa Gomez¹⁰, Amy M. DeLozier¹⁰, Jonathan Janes¹⁰, Matthew D Linnik¹⁰, Stephanie de Bono¹⁰, Maria E. Silk¹⁰ and Robert W. Hoffman¹⁰, ¹Cedars-Sinai Medical Center/David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ²Division of Rheumatology, Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴University of California at San Diego School of Medicine, La Jolla, CA, ⁵University of Pisa, Pisa, Italy, ⁶Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Charité Universitätmedizin Berlin and Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany, ⁸Centro de Investigación Clínica de Morelia SC, Morelia, Mexico, ⁹Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, United Kingdom, ¹⁰Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (Bari), an oral selective inhibitor of Janus kinase (JAK)1 and JAK2, has been approved for the treatment of RA in the Europe and…
Abstract Number: 1518 • 2018 ACR/ARHP Annual Meeting
Baricitinib and Tofacitinib in Real Life – Does Obesity Impact Response to Janus Kinase Inhibitor Therapy in Rheumatoid Arthritis?
Yvette Meißner¹, Lisa Baganz¹, Matthias Schneider², Ilka Schwarze³, Martin Feuchtenberger⁴, Angela Zink⁵ and Anja Strangfeld⁶, ¹Programme Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Department of Rheumatology & Hiller Research Unit, Medical Faculty, University Hospital, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ³Praxis internistische Rheumatologie, Leipzig, Germany, ⁴Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ⁵Epidemiology Unit / Rheumatology and Clinical Immunology, German Rheumatism Research Centre (DRFZ) / Charité University Hospital, Berlin, Germany, ⁶Epidemiology, German Rheumatism Research Center, Berlin, Germany
Background/Purpose: The influence of obesity on treatment response of tumor necrosis factor inhibitors in patients with rheumatoid arthritis (RA) is described in literature, but data…
Abstract Number: 1530 • 2018 ACR/ARHP Annual Meeting
CRP Changes during Bacterial Infections in Baricitinib-Treated Patients with RA
Oliver Hendricks¹, Stavros Chrysidis², Jens Gerwien³, Chadi Saifan³, Francesco de Leonardis³, Pedro Lopez-Romero³, Jinglin Zhong⁴, Kevin Winthrop⁵ and Josef S. Smolen⁶, ¹King Chr.Xs Rheumatology Hospital, Graasten, Denmark, ²Rheumatology Department Sydvestjysk Sygehus, Esbjerg, Denmark, ³Eli Lilly and Company, Indianapolis, IN, ⁴Quintiles, Rockville, MD, ⁵Oregon Health Sciences University, Portland, OR, ⁶Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Background/Purpose: Baricitinib (BARI) is a selective inhibitor of Janus kinase 1/2, modulating responses to inflammatory cytokines, e.g. IL-6 or IFNs1. During acute inflammation, including those…
Abstract Number: 1536 • 2018 ACR/ARHP Annual Meeting
Mean Platelet Volume Changes with Baricitinib Indicate Reduced New Platelet Production in Baricitinib-Treated Rheumatoid Arthritis Patients
Jon T. Giles¹, Michael T. Nurmohamed², Henry M. Rinder³, Venkatesh Krishnan⁴, Brenda J. Crowe⁴, Chadi Saifan⁴ and Thomas Dörner⁵, ¹Columbia University, New York, NY, ²VU University Medical Center, Amsterdam, Netherlands, ³Yale University School of Medicine, New Haven, CT, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Charité Universitätsmedizin Berlin and Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Germany
Background/Purpose: Transient increases in circulating platelets were observed in patients with RA treated with baricitinib, an oral selective Janus kinase 1/2 inhibitor, approved for the…
Abstract Number: 1894 • 2018 ACR/ARHP Annual Meeting
Baricitinib-Associated Changes in Type l Interferon Gene Signature during a 24-Week Phase-2 Clinical SLE Trial
Thomas Dörner¹, Yoshiya Tanaka², Michelle Petri³, Josef S. Smolen⁴, Ernst R. Dow⁵, Richard E. Higgs⁵, Robert J. Benschop⁵, Adam Abel⁵, Maria E. Silk⁵, Stephanie de Bono⁵ and Robert W. Hoffman⁵, ¹Charité Universitätsmedizin Berlin and Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Germany, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁵Eli Lilly and Company, Indianapolis, IN
Background/Purpose: In the phase 2 study JAHH (NCT02708095), treatment with baricitinib (bari), an oral selective Janus kinase 1/2 inhibitor approved for the treatment of RA,…
Abstract Number: 2035 • 2018 ACR/ARHP Annual Meeting
Effect of Baricitinib on Joint-Related Biomarkers in Patients with Moderate-to-Severe Rheumatoid Arthritis
Christian S. Thudium¹, Anne C. Bay-Jensen¹, Suntara Cahya², Ernst R. Dow², Morten A. Karsdal¹, Alisa E. Koch², Wenling Zhang² and Robert J. Benschop², ¹Nordic Bioscience, Herlev, Denmark, ²Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (bari) is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK2. In the phase 3 study RA-BUILD (NCT01721057), once-daily bari yielded…
Abstract Number: 2531 • 2018 ACR/ARHP Annual Meeting
Assessment of Pain Relief with Baricitinib By Treatment History in Patients with Refractory Rheumatoid Arthritis
Janet E. Pope¹, Amanda Quebe², Baojin Zhu², Luna Sun², Carol L. Gaich², Francesco de Leonardis², Anabela Cardoso² and Mark C. Genovese³, ¹St. Joseph's Health Care, Divsion of Rheumatology, London, ON, Canada, ²Eli Lilly and Company, Indianapolis, IN, ³Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Baricitinib (BARI) 2 mg and 4 mg once daily demonstrated significant clinical improvements compared to placebo in the phase 3 study of RA patients…
Abstract Number: 2815 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Safety – Update from up to 6 Years of Treatment with Baricitinib in Rheumatoid Arthritis Clinical Trials
Michael Weinblatt¹, Peter C. Taylor², Gerd R. Burmester³, Chadi Saifan⁴, Chad D. Walls⁴, Maher Issa⁴, Terence P. Rooney⁴ and Tsutomu Takeuchi⁵, ¹Brigham and Women’s Hospital, Boston, MA, ²Botnar Research Centre, Univ of Oxford, Oxford, United Kingdom, ³Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Baricitinib (BARI), a selective inhibitor of Janus kinases, is approved in >40 countries for the treatment of active rheumatoid arthritis (RA) in adults. Patients…

Baricitinib 4 Mg and 2 Mg Once Daily Reduced Pain in Both Patients Who Were Opioid Users and Non-users in Active Rheumatoid Arthritis: A Post-hoc Analysis of Phase 3 Trials

Safety of Baricitinib Under Clinical Settings in Patients with Rheumatoid Arthritis, Using Data from All-Case Post-marketing Surveillance and Spontaneous Reports

Baricitinib: Early Vs. Delayed Start in Patients with Rheumatoid Arthritis

Longitudinal Efficacy Analysis of Patients with Active Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Dmards: Response Following Rescue from Baricitinib 2mg to 4mg Once-Daily

Comparative Effectiveness in Pain and HAQ-DI Improvement for Baricitinib Versus Adalimumab, Tocilizumab, and Tofacitinib Monotherapies in Csdmard-Naïve Rheumatoid Arthritis Patients: A Matching-Adjusted Indirect Comparison (MAIC)

Efficacy and Safety of Switching from Adalimumab to Baricitinib: Long-Term Data from Phase 3 Extension Study in Patients with Rheumatoid Arthritis

Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 6 Years: An Updated Integrated Safety Analysis

Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

Baricitinib and Tofacitinib in Real Life – Does Obesity Impact Response to Janus Kinase Inhibitor Therapy in Rheumatoid Arthritis?

CRP Changes during Bacterial Infections in Baricitinib-Treated Patients with RA

Mean Platelet Volume Changes with Baricitinib Indicate Reduced New Platelet Production in Baricitinib-Treated Rheumatoid Arthritis Patients

Baricitinib-Associated Changes in Type l Interferon Gene Signature during a 24-Week Phase-2 Clinical SLE Trial

Effect of Baricitinib on Joint-Related Biomarkers in Patients with Moderate-to-Severe Rheumatoid Arthritis

Assessment of Pain Relief with Baricitinib By Treatment History in Patients with Refractory Rheumatoid Arthritis

Cardiovascular Safety – Update from up to 6 Years of Treatment with Baricitinib in Rheumatoid Arthritis Clinical Trials

Simple Search Results